Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with HER2-positive breast cancer through a needle biopsy or surgery at Peking University People's Hospital.
- People who received treatment at that hospital and had surgery to remove the breast cancer, with hospital records available.
- People who received standard HER2-targeted treatment, which may include trastuzumab, trastuzumab combined with pertuzumab, or T-DM1, either before or after surgery.
- People who have signed an agreement to take part in the Peking University People's Hospital breast disease cohort study.
Who may not be able to join:
- People whose medical records are incomplete, such as missing imaging results or pathology reports.
- People whose breast cancer has spread to other parts of the body, or who have cancer in both breasts.
- People who did not have surgery aimed at fully removing the cancer.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: shu wang, doctor, Peking University People's Hospital
Phone: 86+13671287670
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
invasive disease free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.